Screening and identification of dietary oils and unsaturated fatty acids in inhibiting inflammatory prostaglandin E2 signaling in fat stromal cells
© Ruan and So; licensee BioMed Central Ltd. 2012
Received: 14 March 2012
Accepted: 23 August 2012
Published: 31 August 2012
The molecular mechanisms of dietary oils (such as fish oil) and unsaturated fatty acids, which are widely used by the public for anti-inflammation and vascular protection, have not been settled yet. In this study, prostaglandin E2 (PGE2)-mediated calcium signaling was used to screen dietary oils and eight unsaturated fatty acids for identification of their anti-inflammatory mechanisms. Isolated fat/stromal cells expressing endogenous PGE2 receptors and an HEK293 cell line specifically expressing the recombinant human PGE2 receptor subtype-1 (EP1) were cultured and used in live cell calcium signaling assays. The different dietary oils and unsaturated fatty acids were used to affect cell signaling under the specific stimulation of a pathological amount of inflammatory PGE2.
It was identified that fish oil best inhibited the PGE2 signaling in the primary cultured stromal cells. Second, docosahexaenoic acid (DHA), found in abundance in fish oil, was identified as a key factor of inhibition of PGE2 signaling. Eicosapentaenoic acid (EPA), another major fatty acid found in fish oil and tested in this study was found to have small effect on EP1 signaling. The study suggested one of the four PGE2 subtype receptors, EP1 as the key target for the fish oil and DHA target. These findings were further confirmed by using the recombinant EP1 expressed in HEK293 cells as a target.
This study demonstrated the new mechanism behind the positive effects of dietary fish oils in inhibiting inflammation originates from the rich concentration of DHA, which can directly inhibit the inflammatory EP1-mediated PGE2 receptor signaling, and that the inflammatory response stimulated by PGE2 in the fat stromal cells, which directly related to metabolic diseases, could be down regulated by fish oil and DHA. These findings also provided direct evidence to support the use of dietary oils and unsaturated fatty acids for protection against heart disease, pain, and cancer resulted from inflammatory PGE2.
KeywordsUnsaturated fatty acid (UFA) Fish oil Anti-inflammation Prostaglandin E2 (PGE2) PGE2 receptor (EP) EP subtype-1 (EP1)
Fish oil and unsaturated fatty acids (UFAs) are widely used as supplements for prevention or treatment of inflammation, vascular diseases, pain, and cancer; however, the health benefits and molecular targets of these compounds have not been clearly identified yet. Nevertheless, many advances have recently been made by searching the molecular targets of fish oil. It is believed that the biological activity of fish oil is related to reducing the excess endogenous prostaglandin E2 (PGE2), which is synthesized through the inducible and inflammatory cyclooxygenase-2 (COX-2) pathway [1, 2]. When cells undergo inflammatory stimulation, an endogenous fatty acid, arachidonic acid (AA), released from the cell membrane, is converted into an intermediator, prostaglandin H2, (by COX-2) and then further converted into PGE2 by PGE2 synthases [3–5]. There are three different PGE2 synthases in cells that have been identified, although the one most associated with inflammatory stimulation is the inducible microsomal PGE2 synthase-1 (mPGES-1) [6, 7]. The inflammatory activity of PGE2 is mediated by its receptors (EPs) on the cell membrane. There are four subtypes of EPs, termed EP1, EP2, EP3 and EP4 which have been cloned, characterized , and identified in inflammatory tissues and cancers [8–13]. When the receptors receive excess PGE2, they immediately begin signaling and cause an increase in intracellular calcium (by EP1 and EP3) or cAMP (by EP2 and EP4) levels which leads to the biological functions of PGE2 – thus causing the inflammation that is directly related to the pathological processes of pain, vascular diseases, and cancer cell growth .
The COX-2/mPGES-1-pathway -induced excess PGE2 signaling plays a key role in inflammation and pain as confirmed by the non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and selective COX-2 inhibitors (Vioxx and Celebrex), which specifically target COX activity [4, 5]. From the century old drug, aspirin [5, 14] to the modern COX-2 inhibitor, Celebrex , all NSAIDS have the same goal: inhibit COX’s ability to reduce excess PGE2 production and signaling. However, non-selective NSAIDs can cause severe stomach insult, such as bleeding.
In this study, we have screened several dietary oils and unsaturated fatty acids for identification of the particular oils and fatty acids with potential use for prevention and treatment of inflammation and its related diseases. We found that fish oil and DHA have the ability to inhibit the inflammatory PGE2 signaling receptor, EP1.
Medium for culturing the cell lines was purchased from Invitrogen. Other reagents were from Sigma. Dietary oils including olive, sesame, canola, fish oils were obtained from the Whole Foods brand 365. Unsaturated fatty acids (ALA, DHA, Erucic acid, EPA, oleic, LA, RA, and AA), Fluo-8 AM and lipase were obtained from Sigma (St. Louis, MO).
The mouse stromal cells expressing endogenous subtype EPs were isolated from mouse fat tissue and cultured using Dulbecco's Modified Eagle's Medium (DMEM) medium with fetal bovine serum (FBS) as described previously . The protocol for the animal fat cell extraction was approved by the University of Houston Institutional Animal Care and Use Committee.
EP1 receptor pcDNA construction
A pAcSG-EP cDNA cloned by our laboratory was first subcloned into EcoRI/XhoI sites of pcDNA3.1 (+) expression vector to generate the plasmid of pcDNA: human EP1. The pcDNA vector has a Cytomegalovirus (CMV) promoter and geneticin (G418) as the selection antibiotic.
Stable expression of recombinant human EP1 in HEK293 cells
The generation of the HEK293 cell line stably expressing human EP1 (HEK293-hEP1) has been described previously . Briefly, HEK293 cells cultured in DMEM containing FBS (10%), antibiotics, and antimycotics were transfected with the purified pcDNA: human EP1 using the Lipofectamine 2000 method . Approximately 48 hours after transfection, the cells were subcultured and incubated with G418 (selection antibiotic) for four weeks to generate the HEK293 cell line stably expressing human EP1 (HEK293-hEP1).
Western blot analysis
The cultured cells were collected and washed with PBS. The proteins were separated by 7-10% (w/v) SDS-PAGE under denaturing conditions and then transferred to a nitrocellulose membrane. Bands recognized by individual primary antibodies were visualized with horseradish peroxidase-conjugated secondary antibody as described .
Digestion of oils
One milliliter of each oil (olive, canola, sesame, and fish) was individually mixed with 10mg of lipase in 50 μl of PBS. The mixtures were vortexed and kept at 37°C for two hours and then centrifuged at 5,000 revolutions per minute (rpm) for five minutes. Supernatants were stored at 4°C.
Determination of PGE2 signaling
The cultured cells were washed twice (1 mL medium/well), and then incubated with new cell culture medium (1 mL/well) containing calcium binding reagent, Fluo-8 (50 μg). After 30 minutes of incubation at 37°C, the cells were washed with serum-free medium three times to remove the excess Fluo-8 that did not enter the cells, and then observed under a Nikon fluorescence microscope (Nikon, Eclipse Ti) using a software (NIS Elements 2.35) designed specifically for calcium signaling. To start the signaling assay, PGE2 (50 μL, 0.12 μM) was added. The increasing fluorescence signal, generated by the calcium bound to Fluo-8 inside the cells through the binding of PGE2 to its receptor, was recorded under the fluorescence microscope and analyzed.
Determination of the effects of the dietary oils on the PGE2-mediated receptor signaling in the cells
A procedure similar to that used above was performed for the determination of the effects of the dietary oils on PGE2-mediated receptor signaling. The only difference was that the PGE2 used was mixed with the digested individual oils at varied concentrations for 5 minutes before being added to the Fluo-8 loaded cells.
Determination of the effects of individual fatty acids on the PGE2-mediated receptor signaling in the cells
Individual fatty acids dissolved in DMSO (10 μl, 10 μM)) were mixed with the PGE2 for five minutes, and then added into Fluo-8-loaded cells. The fluorescence changes were recorded under the fluorescence microscope. The PGE2 mixed with PBS was used as control.
To observe the intensity of the fluorescence signaling mediated by the PGE2 in the absence and presence of the dietary oils and fatty acids, the specific effects of the dietary oils and fatty acids on the PGE2 signaling were identified by the comparison of the their signal intensities. After analyzing the control cells results, the results were plotted to show the difference between the oils and fatty acids. The experiments were repeated three times.
Student’s t-test was used as the statistical analysis tool.
The expression of endogenous PGE2 receptors in fat stromal cells
Mimicking the gastrointestinal tract to digest oils
Identification of the excessive inflammatory PGE2 induced EP1 signaling in the fat stromal cells using the highly sensitive Fluo-8 as a calcium indicator
Determination of the effects of the digested dietary oils on PGE2-mediated receptor signaling in the live cells
PGE2 signaling affected by the different concentrations of fish oil
The effects of individual UFAs on the PGE2-mediated receptor signaling in the cells
Confirmation of the fish oil specifically inhibiting EP1 calcium signaling using recombinant human EP1 expressed in HEK293 cells
COX-2 inhibitors can increase the risk for heart disease, which is a serious side effect because the COX-produced intermediator, PGH2, is also a substance used for producing the vascular protective molecule, prostacyclin . Thus, finding supplements as alternatives to the selective and non-selective NSAIDs to reduce and prevent inflammation is of high importance. Some UFA-rich dietary oils with unsaturated fatty acids such as fish oil have been found to have anti-inflammatory functions. Most reports focused on the observation and confirmation that dietary oils could reduce PGE2 biosynthesis through competition with AA on the substrate-binding site of COXs [17, 18]. However, we found that the fish oil was not very effective in inhibiting COX-2/mPGES-1 activities via inhibition of the inflammatory PGE2 biosynthesis, and thus may be doing so through another mechanism. Based on the fact that PGE2 is derived from a UFA, and that UFA molecules have similar structures to PGE2, we can safely say that molecules which have similar structures to PGE2 may bind to some target molecules, such as EPs, and in turn block PGE2 signaling. In this case, the similar UFA molecules may act as antagonists against inflammation. Many drugs have been developed for treatment of diseases based on the antagonist principle. The search for an “antagonist” to compete with PGE2 in binding to the receptor and block its signaling is an important step towards finding something that can reduce PGE2, yet maintain COX activity for production of the vascular protector, prostacyclin. This information has led us to hypothesize that if dietary oils contain unsaturated fatty acids with similar structures to that of PGE2, then fish oil and certain omega-3 fatty acids may have the ability to block PGE2 from binding to its receptors and then inhibit signaling, resulting in reduced inflammation. In this paper, we tested this hypothesis and found a novel mechanism of dietary oils and UFAs showing anti-inflammatory potential through inhibiting EP signaling. The study has provided important evidence that fish oil and one of its major ingredients, DHA, have the ability to inhibit PGE2 signaling, which highlights the benefit of taking fish oil as a supplement for health, including preventing inflammation, cancers and heart diseases.
Many studies have shown that the use of UFAs, such as omega-3 fat acid and the UFA-rich dietary oils, can benefit in the prevention and reduction of inflammation that is involved in promoting heart disease, cancer, arthritis, and pain. However, little information is available regarding the effects of the dietary oils and UFAs on specific inflammatory PGE2 signaling (mediated by receptors) that are considered better targets for developing novel therapeutic interventions against inflammation. Our study has found that fish oil has a significant effect on inhibition of PGE2 binding to the EP1 receptor and thus inhibiting the signaling (Figure 5). The observation was further confirmed by a dose response assay, in which the IC50 was established (Figure 6). These results suggested that the fish oil could also likely bind to the other subtype PGE2 receptors, EP2, EP 3 and EP 4 and inhibit their signaling. This led to the conclusion that dietary fish oil can reduce PGE2-mediated inflammation. Therefore, consuming fish oil can reduce major risk factors of cancers, heart disease, arthritis, and pain. In contrast, olive oil, canola oil and sesame oil have altered PGE2 signaling patterns (delaying or prolonging signaling, Figure 5), but have less effects on inhibition of PGE2-mediated calcium signaling. Thus, taking these oils may not yield results as strong as fish oil for the prevention of cancers, heart disease, arthritis, and pain caused by excess inflammatory PGE2.
To further identify the active ingredient in the fish oil involved in the inhibition of PGE2 binding to its receptors, screenings of the inhibitory activities of the UFAs (major ingredients in the dietary oils) were performed. Among the eight UFAs present in the dietary oils, DHA best inhibits PGE2-signaling. Data analysis has determined that fish oil contains high concentrations of DHA compounds, which provides strong scientific evidence supporting the study in which fish oil has superior inflammation inhibiting abilities. Previously, researchers had found that fish oil high in DHA and low in EPA reduced inflammation, but were unaware of the mechanisms behind this conclusion [17, 18]. This study has provided a novel finding and evidence that fish oil and DHA have anti-inflammatory effects through inhibiting PGE2 receptor signaling.
The study not only provided the mechanism behind fish oil and DHA acting on receptor levels, but also quantitatively measured the effect of the fish oil on inhibiting PGE2 signaling, which provides important information on how to effectively supplement with fish oil. In Figure 6B, the IC50 for fish oil is about 0.02 μl (0.018 mg) in a total of 1000 μl (1.0 ml) cell solution. Thus, the IC50 for fish oil is approximately 18 mg/L or 54 μM (using the average molecular weight of fatty acids with 300 Daltons). There are 4–5 liters of bloods in a 150 pound body. This means that consuming 100 mg fish oil should yield IC50 results. If given 5 to 10 times the IC50, then taking 500 –1000 mg fish oil daily is recommended based on the findings in this study.
Finally, we conclude that fish oil is a promising dietary oil used to prevent and reduce inflammation-mediated diseases, such as heart diseases, cancers, arthritis, and pain. The mechanism behind the benefits of fish oil is not only to interfere with PGE2 biosynthesis as reported previously, but more importantly the fish oil has the ability to inhibit the inflammatory factor, PGE2 binding to its receptor and thereby reduce the inflammatory signaling. In other words, fish oil can be taken by people striving to reduce risks of heart disease, cancer, and arthritis. This study also revealed that the mechanism behind the inhibiting of PGE2 signaling of fish oils comes from the rich concentrations of DHA, which have the ability to directly inhibit PGE2 signaling. These findings may greatly affect people that consume dietary oils on a daily basis, and also those concerned with protecting themselves against health risks, cancer and pain. This study was an attempt to find a novel mechanism for the fish oil and UFA on inhibition of the inflammation. However, it should be noted that other possibilities and pathways should not be excluded.
This project was supported by the Center for Experimental Therapeutics and PharmacoInformatics at the University of Houston and Bellaire High School Science Club. Additionally, we thank the 51st Annual Science the Engineering fare of Greater Houston which was awarded the first place (in medicine category) for DR, and the Houston Nutrition Association with a special award to DR based on the unpublished poster presentation.
- Dossier, Inflammation mechanism related to PGE2 synthase (. (05/11/2009)http://www.angelini.it/inflammation-pge2/dossier-pharma/channelId/11003/pageTypeId/10552/channelPage/archive_dossiers/contentTypeId/2/contentId/15009/programId/14891
- Chillar AJ, Karimi P, Tang K, Ruan KH: An agonist sensitive, quick and simple cell-based signaling assay for determination of ligands mimicking prostaglandin E2 or E1 activity through subtype EP1 receptor: Suitable for high throughput screening. BMC Complement Altern Med. 2011, 11: 11-10.1186/1472-6882-11-11. PMID: 21299883View ArticlePubMedPubMed CentralGoogle Scholar
- Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA. 89 (16): 7384-7388. PMID: 1380156Google Scholar
- Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001, 294 (5548): 1871-1875. 10.1126/science.294.5548.1871. PMID: 11729303View ArticlePubMedGoogle Scholar
- Vane JR: Biomedicine. Back to an aspirin a day?. Science. 2002, 296 (5567): 474-10.1126/science.1071702. PMID: 11964462View ArticlePubMedGoogle Scholar
- Murakami M, Nakatani Y, Tanioka T, Kudo I: Prostaglandin E synthase. Prostaglandins Other Lipid Mediat. 2002, 68–69: 383-399. PMID 12432931View ArticlePubMedGoogle Scholar
- Park JY, Pillinger MH, Abramson SB: Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol. 2006, 119 (3): 229-240. PMID 16540375.View ArticlePubMedGoogle Scholar
- McCoy JM, Wicks JR, Audoly LP: The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest. 2002, 110: 651-658. PMID: 12208866View ArticlePubMedPubMed CentralGoogle Scholar
- Miyata Y, Kanda S, Maruta S, Matsuo T, Sakai H, Hayashi T, Kanetake H: Relationship between prostaglandin E2 receptors and clinicopathologic features in human prostate cancer tissue. Urology. 2006, 68 (6): 1360-1365. 10.1016/j.urology.2006.09.035. PMID: 17169665View ArticlePubMedGoogle Scholar
- Su JL, Shih JY, Yen ML: Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res. 2004, 64 (2): 554-564. PMID 14744769.View ArticlePubMedGoogle Scholar
- Han C, Wu T: Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem. 2005, 280 (25): 24053-24063. PMID 15855163.View ArticlePubMedGoogle Scholar
- Han C, Michalopoulos GK, Wu T: Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol. 2006, 207 (1): 261-270. PMID 16331686.View ArticlePubMedGoogle Scholar
- Durrenberger PF, Facer P, Casula MA: Prostanoid receptor EP1 and Cox-2 in injured human nerves and a rat model of nerve injury: a time-course study. BMC Neurol. 2006, 6: 1-PMID 16393343.View ArticlePubMedPubMed CentralGoogle Scholar
- Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971, 231: 232-235. PMID: 5284360View ArticlePubMedGoogle Scholar
- Ruan KH, Mohite A, So SP, Ruan CH: Establishing novel prostacyclin-synthesizing cells with therapeutic potential against heart diseases. Int J Cardiol. 2011, Jun 29. [Epub ahead of print] PMID: 21722977Google Scholar
- Vedin I, Cederholm T, Freund Levi Y, Basun H, Garlind A: Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am J Clin Nutr. 2008, 87: 1616-1622. PMID: 18541548PubMedGoogle Scholar
- Science News: More Fish Oil, Less Vegetable Oil, Better For Your Health, Science Daily. 2007,http://www.sciencedaily.com/releases/2007/07/070726162224.htm,Google Scholar
- Moghadasian MH: Advances in dietary enrichment with n-3 fatty acids. Crit Rev Food Sci Nutr. 2008, 48 (5): 402-410. 10.1080/10408390701424303. PMID: 18464030View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/12/143/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.